Molecular targets in therapy for human soft-tissue and bone sarcomas

Current Oncology Reports

Volumn 5, Issue 4, 2003, Pages 295-303

  Steinert, Dejka M ^a   Blakely, L Johnetta ^a   Salganick, Jason ^a   Trent, Jonathan C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN; APOLIPOPROTEIN 2; CAMPTOTHECIN DERIVATIVE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GROWTH FACTOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; LOPERAMIDE; MELPHALAN; METHOTREXATE; OBLIMERSEN; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; TOPOTECAN; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CARCINOGENESIS; CLINICAL TRIAL; CYTOPATHOLOGY; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; FATIGUE; FEVER; FLUSHING; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; MOLECULAR DYNAMICS; OSTEOSARCOMA; PLASMA CELL GRANULOMA; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; BONE TUMOR; CONTROLLED CLINICAL TRIAL; FEMALE; GENE THERAPY; MALE; METHODOLOGY; MORTALITY; ONCOGENE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SARCOMA; SOFT TISSUE TUMOR; SURVIVAL; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

BONE NEOPLASMS; FEMALE; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; ONCOGENES; OSTEOSARCOMA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037658619     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0069-8     Document Type: Review

References (80)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
2. Jemal A, Thomas A, Murray T, et al.: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
3. Patel S, Vadhan-Raj S, Burgess M, et al.: Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998, 21:317-321.
4. Patel S, Vadhan-Raj S, Papadopoulos N, et al.: High-dose ifosfamide in bone and soft-tissue sarcomas: results of phase II and pilot studies - dose response and schedule dependence. J Clin Oncol 1997, 15:2378-2384.
5. Picci P, Bacci G, Ferrari S, et al.: NEoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Ann Oncol 1997, 8:1107-1115.
6. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
7. Slominski A, Wortsman J, Carlson A, et al.: Molecular pathology of soft tissue and bone tumors: a review. Arch Pathol Lab Med 1999, 123:1246-1259.
8. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
9. Gottlieb J, Baker L, O'Bryan R, et al.: Adriamycin (NSC-123-127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep 1974, 6:271-282.
10. von Mehren M, Blanke C, Joensuu H, et al.: High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs) [abstract]. Proc ASCO 2002, 21:1608.
11. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052-1056.
12. Allam M, Martinet N, Martinet Y: Differential migratory response of U-2 OS osteosarcoma cell to the various forms of platelet-derived growth factor. Biochimie 1992, 74:183-186.
13. Badache A, De Vries GH: Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J Cell Physiol 1998, 177:334-342.
14. Fahrer C, Brachmann R, von der Helm K: Expression of c-sis and other cellular proto-oncogenes in human sarcoma cell lines and biopsies. Int J Cancer 1989, 44:652-657.
15. Gisselsson D, Hoglund M, O'Brien KP, et al.: A case of dermatofibrosarcoma protuberans with a ring chromosome 5 and a rearranged chromosome 22 containing amplified COL1A1 and PDGFB sequences. Cancer Lett 1998, 133:129-134.
16. Benito M, Lorenzo M: Platelet derived growth factor/tyrosine kinase receptor mediated proliferation. Growth Regul 1993, 3:172-179.
17. Werner S, Hofschneider PH, Heldin CH, et al.: Cultured Kaposi's sarcoma-derived cells express functional PDGF A-type and B-type receptors. Exp Cell Res 1990, 187:98-103.
18. Clarke MF, Westin E, Schmidt D, et al.: Transformation of NIH 3T3 cells by a human c-sis cDNA clone. Nature 1984, 308:464-467.
19. Betsholtz C, Westermark B, Ek B, et al.: Coexpression of a PDGF-like growth factor and PDGF receptors in a human osteosarcoma cell line: implications for autocrine receptor activation. Cell 1984, 39:447-457.
20. Kazlauskas A, Bowen-Pope D, Seifert R, et al.: Different effects of homo- and heterodimers of platelet-derived growth factor A and B chains on human and mouse fibroblasts. Embo J 1988, 7:3727-3735.
21. Callahan M, Cochran BH, Stiles CD: The PDGF-inducible 'competence genes': intracellular mediators of the mitogenic response. Ciba Found Symp 1985, 116:87-97.
22. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999, 79:1283-1316.
23. O'Brien KP, Seroussi E, Dal Cin P, et al.: Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 1998, 23:187-193.
24. Sjoblom T, Shimizu A, O'Brien KP, et al.: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001, 61:5778-5783.
25. Maki RG, Awan RA, Dixon RH, et al.: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002, 100:623-626.
26. Coffin CM, Watterson J, Priest JR, et al.: Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor): a clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 1995, 19:859-872.
27. Souid AK, Ziemba MC, Dubansky AS, et al.: Inflammatory myofibroblastic tumor in children. Cancer 1993, 72:2042-2048.
28. Cook JR, Dehner LP, Collins MH, et al.: Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 2001, 25:1364-1371.
29. Arber DA, Weiss LM, Chang KL: Detection of Epstein-Barr virus in inflammatory pseudotumor. Semin Diagn Pathol 1998, 15:155-160.
30. Gomez-Roman JJ, Sanchez-Velasco P, Ocejo-Vinyals G, et al.: Human herpesvirus-8 genes are expressed in pulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). Am J Surg Pathol 2001, 25:624-629.
31. Coffin CM, Dehner LP, Meis-Kindblom JM: Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations. Semin Diagn Pathol 1998, 15:102-110.
32. Su LD, Atayde-Perez A, Sheldon S, et al.: Inflammatory myofibroblastic tumor: cytogenetic evidence supporting clonal origin. Mod Pathol 1998, 11:364-368.
33. Snyder CS, Dell'Aquila M, Haghighi P, et al.: Clonal changes in inflammatory pseudotumor of the lung: a case report. Cancer 1995, 76:1545-1549.
34. Griffin CA, Hawkins AL, Dvorak C, et al.: Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999, 59:2776-2780.
35. Morris SW, Kirstein MN, Valentine MB, et al.: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284.
36. Lawrence B, Perez-Atayde A, Hibbard MK, et al.: TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000, 157:377-384.
37. Lamant L, Dastugue N, Pulford K, et al.: A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999, 93:3088-3095.
38. Coffin CM, Patel A, Perkins S, et al.: ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001, 14:569-576.
39. Zhang Q, Raghunath PN, Xue L, et al.: Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 2002, 168:466-474.
40. Sausville EA, Arbuck SC, Messmann R, et al.: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001, 19:2319-2333.
41. Shmitt C, Fridman J, Yang M, et al.: A senescence program controlled by p53 and p16(INK4a) contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
42. Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
43. Reed JC: Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999, 11:68-75.
44. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995, 7:541-546.
45. Matsuyama S, Reed JC: Mitochondria-dependent apoptosis and cellular PH regulation: Cell Death Differ 2000, 7:1155-1165.
46. Gao CF, Ren S, Zhang L, et al.: Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis. Exper Cell Res 2001, 265:145-151.
47. Thornberry NA, Lazebnik Y: Caspases: enemies within. Science 1998, 281:1312-1316.
48. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992, 80:879-886.
49. Suster S, Fisher C, Moran CA, et al.: Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998, 22:863-872.
50. Cunningham RE, Abbondanzo SL, Chu WS, et al.: Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stromal/smooth muscle tumors. Appl Immunohistochem Mol Morphol 2001, 9:19-23.
51. Kitada S, Takayama S, De Riel K, et al.: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994, 4:71-79.
52. Smith MR, Abubakr Y, Mohammad R, et al.: Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther 1995, 2:207-212.
53. Geary RS, Leeds JM, Henry SP, et al.: Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 1997, 12:383-393.
54. Webb A, Cunningham D, Cotter F, et al.: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997, 349:1137-1141.
55. Waters JS, Webb A, Cunningham D, et al.: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000, 18:1812-1823.
56. Raynaud FI, Orr RM, Goddard PM, et al.: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 1997, 281:420-427.
57. Jansen B, Schlagbauer-Wadl H, Brown BD, et al.: bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998, 4:232-234.
58. Sheridan JP, Marsters SA, Pitti RM, et al.: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821.
59. Evdokiou A, Bouralexis S, Atkins GJ, et al.: Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002, 99:491-504.
60. Marsters SA, Sheridan JP, Pitti RM, et al.: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997, 7:1003-1006.
61. Zhang XD, Franco AV, Nguyen T, et al.: Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000, 164:3961-3970.
62. Griffith TS, Chin WA, Jackson GC, et al.: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998, 161:2833-2840.
63. Ashkenazi A, Pai RC, Fong S, et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162.
64. Jo M, Kim TH, Seol DW, et al.: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000, 6:564-567.
65. Lawrence D, Shahrokh Z, Marsters S, et al.: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001, 7:383-385.
66. Lacour S, Hammann A, Wotawa A, et al.: Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001, 61:1645-1651.
67. Mizutani Y, Nakao M, Ogawa O, et al.: Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 2001, 165:263-270.
68. Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991, 51:3075-3079.
69. Hsiang YH, Hertzberg R, Hecht S, et al.: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260:14873-14878.
70. Champoux JJ, Dulbecco R: An activity from mammalian cells that untwists superhelical DNA: a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay). Proc Natl Acad Sci U S A 1972, 69:143-146.
71. Rothenberg ML: Topoisomerase I inhibitors: review and update. Ann Oncol 1997, 8:837-855.
72. Bissery MC, Vrignaud P, Lavelle F, et al.: Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 1996, 7:437-460.
73. Rothenberg ML, Kuhn JG, Burris HA III, et al.: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993, 11:2194-2204.
74. Rowinsky EK, Grochow LB, Ettinger DS, et al.: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994, 54:427-436.
75. Abigerges D, Chabot GG, Armand JP, et al.: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995, 13:210-221.
76. de Forni M, Bugat R, Chabot GG, et al.: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994, 54:4347-4354.
77. Houghton JA, Cheshire PJ, Hallman JD II, et al.: Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res 1996, 2:107-118.
78. Houghton PJ, Cheshire PJ, Hallman JD II, et al.: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995, 36:393-403.
79. Furman WL, Stewart CF, Poquette CA, et al.: Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999, 17:1815-1824.
80. Cosetti M, Wexler LH, Calleja E, et al.: Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 2002, 24:101-105. x